Drugs / ARUNDINE
ARUNDINE
also known as
diindolylmethane · BioResponse-DIM · DIM · 1,1-bis(3'-indolyl)methane · 3,3'-diindolylmethane · B-DIM
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03802721 | Jan 2019 → Jan 2024 | exposure, dental pulp | Oregon State University | Completed | No outcome recorded |
| Phase 14 trials | ||||||
| Phase 1 | NCT00450229 | Feb 2007 → Feb 2010 | prostate adenocarcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00392652 | Nov 2006 → Oct 2008 | — | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00305747 | Aug 2005 → Sep 2010 | prostate cancer | Barbara Ann Karmanos Cancer Institute | Completed | No outcome recorded |
| Phase 1 | NCT00784394 | Apr 2004 → Oct 2009 | — | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01612910 | Jun 2012 → Feb 2014 | female breast carcinoma | Barbara Ann Karmanos Cancer Institute | Withdrawn | No outcome recorded |
| Phase 2 | NCT00888654 | Aug 2009 → Apr 2014 | prostate cancer | Barbara Ann Karmanos Cancer Institute | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT00462813 | Oct 2004 → Jun 2008 | cervical cancer, precancerous condition | Barts and the London School of Medicine and Dentistry | Completed | No outcome recorded |
| Phase 3 | NCT00212381 | Sep 2000 → Jan 2006 | dysplasia of cervix | New York Presbyterian Hospital | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ARUNDINE | ChEMBL registry synonym — accepted as the source's own label CHEMBL446452 ↗ |
| Known as | 1,1-bis(3'-indolyl)methane | ChEMBL registry synonym — accepted as the source's own label CHEMBL446452 ↗ |
| Known as | 3,3'-diindolylmethane | “ingestion of about 50 g Brussels sprouts or 300 mg of 3,3'-diindolylmethane (DIM) supplement for 7 days prior to the \[14C\]-BaP micro-dose” NCT03802721 ↗ |
| Known as | B-DIM | “after treatment with oral microencapsulated diindolylmethane (B-DIM) in patients with stage I or II adenocarcinoma of the prostate undergoing radical prostatectomy.” NCT00888654 ↗ |
| Known as | BioResponse-DIM | “An Investigation Into the Effects of Diidolylmethane (BioResponse DIM®) Supplementation in Women With Low-Grade Cervical Cytological Abnormalities [CRISP-1]” NCT00462813 ↗2“absorption-enhanced diindolylmethane (BioResponse-DIM” NCT00305747 ↗ “diindolylmethane (DIM) (BioResponse-DIM, BioResponse” PMID 19939441 ↗ Nov 2009 |
| Known as | diindolylmethane | “after treatment with oral microencapsulated diindolylmethane (B-DIM) in patients with stage I or II adenocarcinoma of the prostate undergoing radical prostatectomy.” NCT00888654 ↗7“absorption-enhanced diindolylmethane (BioResponse-DIM” NCT00305747 ↗ “diindolylmethane (DIM) (BioResponse-DIM, BioResponse” PMID 19939441 ↗ Nov 2009 |
| Known as | DIM | “ingestion of about 50 g Brussels sprouts or 300 mg of 3,3'-diindolylmethane (DIM) supplement for 7 days prior to the \[14C\]-BaP micro-dose” NCT03802721 ↗1“diindolylmethane (DIM) (BioResponse-DIM, BioResponse” PMID 19939441 ↗ Nov 2009 |
| Modality | Small molecule | — CHEMBL446452 ↗ |
| Route | Oral | “orally at approximately 2 mg/kg/day for 12 weeks or placebo” PMID 19939441 ↗ Nov 2009 |